ACADIA Pharmaceuticals Inc.

ACAD · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.3%

Institutions99.8%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$1.07B	$957.80M	$517.24M	$484.14M	$441.75M	$339.08M	$223.81M	$124.90M	$17.33M	$61000
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$89.00M	$81.84M	$10.17M	$10.84M	$10.21M	$11.34M	$12.38M	$9.08M	$3.08M	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$104.81M	$230.79M	-$223.60M	-$170.44M	-$286.59M	-$246.54M	-$247.44M	-$292.41M	-$272.81M	-$164.61M
Operating income as a percentage of revenue.	9.8%	24.1%	-43.2%	-35.2%	-64.9%	-72.7%	-110.6%	-234.1%	-1574.1%	-269855.7%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$391.00M	$226.45M	-$215.97M	-$167.87M	-$281.58M	-$235.26M	-$245.19M	-$289.40M	-$271.39M	-$164.44M
Net income divided by the number of shares outstanding — profit attributable to each share.	$2.32	$1.37	$-1.34	$-1.05	$-1.79	$-1.60	$-1.00	$-2.00	$-2.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$2.30	$1.36	$-1.34	–	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$177.69M	$319.59M	$114.85M	$147.44M	$326.03M	$189.68M	$134.76M	$69.42M	$163.62M	$102.14M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.56B	$1.19B	$587.81M	$700.12M	$782.62M	$783.18M	$540.20M	$384.51M	$561.15M	$221.90M
Everything the company owes — debt, unpaid bills, and other obligations.	$336.81M	$454.96M	$187.40M	$159.23M	$155.61M	$84.05M	$61.12M	$49.22M	$42.74M	$22.13M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$1.23B	$732.79M	$400.41M	$540.89M	$627.01M	$699.13M	$479.08M	$335.29M	$518.41M	$199.76M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$109.84M	$157.72M	-$114.03M	-$125.66M	-$136.17M	-$151.13M	-$167.47M	-$217.86M	-$210.41M	-$121.80M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$4.69M	$523000	$0	$1.12M	$7.59M	$1.13M	$2.15M	$812000	$1.51M	$2.14M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$105.15M	$157.20M	-$114.03M	-$126.78M	-$143.75M	-$152.26M	-$169.62M	-$218.67M	-$211.91M	-$123.94M

	You	Peer avg
P/E	12.6	–
Revenue Growth	+16.4%	+101.5%
ROE	35.7%	-94.0%

ACADIA Pharmaceuticals Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison